Investor Presentaiton

R&D Investments R&D Expenditure 7.8% 6.2% 5.8% 5.6% 6.3% 6.5% 7.2% 7.0 4.4 3.3 3.3 2.5 10.4 Filings and Approvals ANDA 599 19.6 445 SUN PHARMA Patents DMF/CEP 401 1443 273 1024 FY09 FY10 FY11 FY12 FY13 FY14 FY15* Filed Approved Filed Approved Filed Granted R&D Exp (% of Net Sales) R&D Expenses (Rs Bn) FY09 - FY14 numbers exclude Ranbaxy financials * FY15 numbers include the impact of Ranbaxy merger © Sun Pharmaceutical Industries Limited. All Rights Reserved. As of Sept 30, 2015 37

View entire presentation